randomized trials without any evidence of improved outcomes yet clearly associated with increased patient toxicity. Additionally, being a small water-soluble molecule with rapid absorption from the i.p. cavity, cisplatin, and carboplatin are not ideal agents for i.p. administration. In fact, macroscopic tumors may actually receive higher cumulative drug exposure from systemic administration compared with direct tumor penetration (i.p. dosing). Indeed, simple measurements of area under the concentration-time curve in peritoneal fluid have failed to document substantial tumor drug penetration of platinum compounds into tumor nodules [7, 8] . Finally, ascites complicates the peritoneal space and develops from disordered capillary architecture, leaky blood vessels, high interstitial pressure, and absent lymphatics.
Paclitaxel on the other hand is a large water insoluble molecule with a clear pharmacologic advantage associated with i.p. administration. Compared with i.v. administration, i.p. paclitaxel has more than an 800-fold increase in the peritoneal to plasma drug level as measured by the area under the concentration-time curve [9] . However, since paclitaxel is so slowly absorbed, some studies have also combined i.p. with i.v. dosing so that the surface and core of the cancer receive cytotoxic doses. Perhaps the most important observation complicating the interpretation of historical positive i.p. trials is the finding in JGOG 3016 that weekly i.v. paclitaxel using increased dosing (dose-dense) improves clinical outcomes including time to progression (PFS) and survival (OS) [10, 11] . Why is this relevant to the interpretation of i.p. chemotherapy clinical trials? The initial three large positive phase III trials suggesting a clinical advantage to i.p. therapy used paclitaxel at an every 3-week schedule. The study where dose dense weekly paclitaxel was integrated into the control arm was definitively negative.
What is the clinical evidence on the benefit of i.p. chemotherapy and why might it not be the standard of care?
'PRO' perspective (Chan) . Three large intergroup phase III trials have demonstrated that i.p. therapy resulted in a 20%-30% reduction in death over i.v. therapy in advanced, low-volume epithelial ovarian cancer (EOC) [12] [13] [14] . The result of Gynecologic Oncology Group (GOG) 172 prompted the National Cancer Institute (NCI) to a clinical alert in January 2006 stating that i.p. chemotherapy improves survival in patients compared with i.v. treatment alone. Subsequent meta-analysis also showed the benefit of i.p. chemotherapy over i.v. treatment [15] .
'CON' perspective (Monk). Despite the positive clinical trial results and the subsequent NCI alert, i.p. treatment has not been widely accepted as the standard of care in the United States and is infrequently used in Europe [4, 16] . The hesitancy of clinicians to use i.p. therapy is likely attributed to higher toxicity, inconvenience, catheter complications, flaws in clinical trial design, and uncertain long-term benefits. More recently, a fourth randomized phase III trial of 1560 subjects has reported negative results [17] . How do we integrate the seemingly contradictory results of these four studies (Table 1) ?
Is i.p. therapy more toxic?
No (Chan) . In the first randomized clinical trial, GOG 104, i.v. therapy was associated with more grade 3 or higher granulocytopenia and leukopenia compared with i.p. treatment [12] . Furthermore, moderate-to-severe tinnitus, hearing loss, and neuromuscular toxic effects were significantly more frequent in the i.v. group. In the subsequent studies, GOG 114 and 172, i.p. therapy was associated with significantly more toxicities compared with i.v. treatment including neutropenia, thrombocytopenia, gastrointestinal, and metabolic toxicity [13, 14] . However, it is important to note that despite the increased toxicity from i.p. therapy in GOG 172, the quality of life measures were comparable between i.v. and i.p. treatment 1-year post-treatment with no increase in deaths from these adverse events [18] . Although GOG 114 and 172 showed worse toxicity in the i.p. group, the most recent study under GOG 252 showed that the overall rates of toxicities and discontinuation among i.v. and i.p. chemotherapy arms were comparable [17] . Unexpectedly, i.p. cisplatin was associated with less grade 3 thrombocytopenia and less grade 2 sensory neuropathy compared with i.v. dose dense chemotherapy. In addition, serious gastrointestinal toxicities were similar with intestinal perforations/fistula/leak occurred in all three arms (range 3.7%-5.3%). Although there was a 6% more grade 3 nausea and vomiting, the overall completion rate of the i.v. dose-dense, i.p. carboplatin, and i.p. cisplatin were similar at 90%, 90%, and 84%, respectively. Most importantly, the 15 deaths possibly due to toxicity were evenly distributed among treatment arms.
Yes (Monk).
Intraperitoneal chemotherapy is clearly more toxic compared with i.v.. Using health-related quality of life questionnaires to minimize the bone marrow, metabolic, pain, intestinal toxicity, and nausea associated with i.p. therapy in GOG 172 seems to be an exaggeration. Indeed, the third arm of GOG 252 included a functional dose reduction of all agents in order to balance toxicity.
What is the long-term results after i.p. therapy?
'PRO' (Chan) . Recently, Tewari et al. analyzed the retrospective data from GOG 114 and 172 comparing i.p. to i.v. therapy among 876 patients in the taxane era [19] . The authors made three primary conclusions: demonstration of an advantage in OS beyond 10 years ( Figure 1A) ; demonstration that i.p. therapy is effective in patients with macroscopic (gross) residual disease <1 cm ( Figure 1B) ; and description of a causative relationship between OS and the number of i.p. cycles delivered ( Figure 1C ).
'CON' (Monk). Despite the apparently practice-changing findings in our long-term analysis of GOG 114 and 172 [19] , many clinicians waited for the results of GOG 252 before integrating i.p. therapy into existing clinical practice. The GOG agreed that 252 would provide the definitive answer to this long debate.
How do we interpret the results of the GOG 252 trials? Is it really a negative study?
No (Chan [17] . Among, 1560 trial participants, the median age was 58 years. Eighty-four percent had stage III disease, 72% had high-grade serous histology, and 57% had no visible residual disease following optimal cytoreduction. Completion rates by treatment arm varied between 59% and Note: Gross residual defined as 1 cm; micro-residual defined as no visible disease [20] . (C) Long-term overall survival based on number of cycles of i.p. therapy (P¼0.03). Analysis restricted to patients in GOG protocol 172 who completed all six cycles of chemotherapy (both i.p. and i.v. arms) [20] . i.p., intraperitoneal; i.v., intravenous.
65%. Cross-over to the i.v. only therapy occurred in 16% randomized to the i.p. carboplatin arm and 28% randomized to i.p. cisplatin arm.
The results of GOG 252 is another advance toward identifying new therapeutic options using novel combinations of bevacizumab with i.p. platinum and paclitaxel in upfront treatment of advance ovarian cancer. Although proponents of i.p. therapy may have projected that i.p. therapy would have continued to show a benefit over i.v. treatment like the prior three randomized trials, there were significant trial designs differences in GOG 252 that may have influenced the results. This trial was design nearly 10 years ago in an attempt to answer numerous clinical questions and forecast the new standard control arm to prevent from being outdated upon its report. During the design of GOG 252 in late 2000s, we anticipated that the weekly paclitaxel and the integration of bevacizumab may become the new standard of care due to the encouraging results of JGOG 3016 [10] and GOG 218 [20] , respectively. Furthermore, GOG 172 had just reported significant toxicities where only 42% completed all six cycles of treatment; as such, the new design reduced the i.p. cisplatin dose according to GOG 9921 [21] in the third arm and included an additional arm substituting i.p. carboplatin for cisplatin based on GOG 9916/17 in arm 2 [22] . With these ambitious goals, the ambiguous results of GOG 252 are not completely unanticipated. Based on the preliminary results of GOG 252, the data suggested that (i) the addition of bevacizumab to all arms of study may have equalized the i.p. treatment with carboplatin and cisplatin to that of i.v. dose dense treatment. The influence of bevacizumab may have also equalized the dose-dense paclitaxel effect over every 3 week paclitaxel as suggested in GOG 262 [11] . (ii) Dose reduction of cisplatin and paclitaxel may have diminished the superiority of i.p. therapy. (iii) The inclusion of suboptimal and stage i.v. disease patients may have attenuated i.p. therapy which has been proven to be most effective in those with minimal residual disease. As this is the first negative trial out of the three positive randomized trials on the benefit of i.p. therapy, we should continue to incorporate i.p. therapy as an option to upfront ovarian cancer due to this new safety and tolerability profile with patient selection. Since younger patients were more likely to complete the six cycles of i.p. regimen, and the risk of death is decreased by 12% for each additional cycle of i.p. chemotherapy, we might be able to use age to better select patients who are able to tolerate this intensive treatment [19] . Using the advances of molecular markers, there is preliminary evidence suggesting that decreased BRCA1 expression predicts for improved response to cisplatin-based i.p. chemotherapy [23] .
Yes (Monk). GOG 252 was a definitively negative trial and ends the debate on i.p. chemotherapy in newly diagnosed ovarian cancer. Intraperitoneal therapy did not confer a significant improvement in PFS over i.v. only, with the median PFS by intent-totreat being 24 Some argue that the integration of bevacizumab into all three arms of GOG 252 somehow interferes with the interpretation of the negative PFS and OS end points. The only cited explanation for this hypothesis is the discrepancy between the results of JGOG 3016 and GOG 262 [10, 11] . The former clinical trial shows that in the absence of bevacizumab, dose-dense weekly chemotherapy confers a clinically important survival benefit while GOG 262 does not when bevacizumab is added. This is counterintuitive relative to GOG 252. If bevacizumab negates the effect of dosedense weekly paclitaxel, then the implications of dose-dense chemotherapy in the control arm of GOG 252 become less relevant meaning that the negative results in this study are even more definitive with bevacizumab not less. Moreover, the PFS of GOG 252 and JGOG 3016 are very similar, one trial with bevacizumab and one without.
Summary of the flawed clinical trial designs and relevance of GOG 172 today
None of these four trials completely defines the role of i.p. chemotherapy in newly diagnosed advanced ovarian cancer. GOG protocol 104 used cyclophosphamide and the assessment of PFS was not recorded. Gynecologic Oncology Group protocol 114 used an induction cycle of high dose chemotherapy and GOG 172 used a weekly and dose intense regimen in the i.p. arm making it impossible to attribute the entire clinical benefit to the i.p. route of administration. Additionally, the doses used in GOG 172 are seemingly too toxic and impractical. Finally, GOG 252 integrated bevacizumab into all three treatment arms. However, GOG 252 is the only trial that isolated the effect of i.p. administration and compared i.p. cisplatin with i.p. carboplatin.
Consensus guidelines
Guidelines can be helpful in creating frameworks for treatment. For example, the National Comprehensive Cancer Network (NCCN) is a well-respected forum for communicating consensus opinions. According to version 1.2017 (12 April 2017) i.p. chemotherapy in women with <1 cm optimally debulked stage III EOC is a category 1 option. In stage II and less common histologic subtypes, it is category 2A. The NCCN notes that 'all women undergoing surgery for ovarian cancer should be counseled about the clinical benefit associated with combined i.v. and i.p. chemotherapy administration before surgery'. The guidelines also emphasize the important role of a multidisciplinary team familiar with catheter management and the value of intense supportive care includes antiemetic regimens. Finally, the fact that elderly and medically infirm patients tolerate i.p. chemotherapy poorly is reiterated [24] .
At the fifth Ovarian Cancer Consensus Conference (OCCC) the Gynecologic Cancer InterGroup held in Tokyo, Japan, in November 2015, representatives of 29 cooperative research groups studying gynecologic cancers gathered to establish international consensus on issues critical to the conduct of randomized trials. In their consensus statement, they recommend that 'the regimen of six cycles of i.v. paclitaxel (175 mg/m 2 ) and carboplatin (AUC 5-6) administered every 3 weeks recommended at the fourth OCCC remains a standard treatment of clinical trials'. In addition, the consensus statement concluded that dose-dense Annals of Oncology Symposium article weekly paclitaxel plus 3-weekly carboplatin or i.p. chemotherapy, as given in GOG 172, could be acceptable control arms in clinical trials. Although these two later regimens differed from 3-weekly carboplatin and paclitaxel in dose, schedule, and route of delivery, they were included as options for a control arm on the basis of at least one clinical trial that showed superiority to the standard i.v. taxane/platinum combination [25] .
Future and ongoing studies
Future large randomized trials are unlikely. However, the Japanese iPocc trial is eagerly anticipated (NCT01506856; Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial). This is a randomized phase II/III trial of i.v. weekly paclitaxel plus i.v. carboplatin once every 3 weeks versus i.v. weekly paclitaxel plus i.p. carboplatin once every 3 weeks in women with EOC. This seemingly pure trial attempts to isolate the effects of i.p. carboplatin but will undoubtedly be open to criticism since it enrolls few Caucasians.
Why i.p. chemotherapy has not widely adopted today
The clinical benefits of i.p. chemotherapy have not been clearly demonstrated across all phase III trials. The hesitancy of clinicians to use i.p. therapy appears to be related to the apparent higher toxicity, inconvenience, catheter complications, as well as flaws in clinical trial design. Additionally, administration of i.p. chemotherapy requires increased resources and cost in terms of both space and time compared with therapy administrated i.v. As of yet, we have not arrived at the optimal i.p. chemotherapy regimen, which balances efficacy with toxicity as well as quality of life.
Perhaps most importantly, the clinical benefit seen in GOG 172 may no longer be relevant now that the results of GOG 252 are known. GOG 252 isolated the effect of i.p. carboplatin and there was no increase in PFS, a seemingly convincingly answer to the controversy. One could argue that the use of bevacizumab should have increased, not decreased, the likelihood of showing a benefit to i.p. therapy because GOG 262 suggested that bevacizumab negates the clinical advantage of dose-dense weekly chemotherapy. In other words, dose-dense weekly paclitaxel (arm 1 of GOG 252) appears to have a similar benefit when compared with i.p. paclitaxel despite the use of bevacizumab but with better tolerability. Even if the iPocc trial is positive, the fact that Asian women with EOC are probably different (pharmacokinetics and increased clear cell histology) than non-Asian women, it will not effectively inform the use of i.p. chemotherapy worldwide.
As noted above, the recent study that reported women with aberrant BRCA1 expression had increased survival when treated with i.p. therapy on GOG 172 is intriguing [23] . This is sometimes used as a rationale to use i.p. therapy in patients with impaired BRCA function. Missing though is the increased efficacy associated with i.v. therapy also seen in patients with dysfunctional BRCA. There is no evidence that platinum dose intensity in more relevant in this subset of patients. In fact, since they are more sensitive to platinum DNA damage, a dose reduction (not increase) may be a more rational strategy.
Despite many years of research, it appears that we have collectively failed to describe the key biologic targets of i.p. therapy in terms of direct tumor cytotoxicity, alterations in the peritoneal stromal microenvironment (such as a reduction in angiogenesis or growth factors), or enhancement of the host immune response. It is clear that each of these pathways are potential mechanisms of clinical benefit for i.p. cytotoxic chemotherapy. Now more than ever, we have novel combinations to personalize upfront treatments for advanced ovarian cancer. In addition to i.p. therapy we also need to focus on targeted therapy, biomarkers, survivorship, and the sequencing of therapy.
